Soluble endoglin for the prediction of preeclampsia in a high risk cohort
Department of Medicine, Division of Preventive and Behavioral Medicine; Department of Obstetrics and Gynecology
Medical Subject Headings
Adult; Antigens, CD; Biological Markers; Enzyme-Linked Immunosorbent Assay; Female; Humans; Pre-Eclampsia; Pregnancy; Pregnancy Proteins; Pregnancy, High-Risk; Pregnancy, Multiple; Receptors, Cell Surface; Risk Factors; Vascular Endothelial Growth Factor Receptor-1
Obstetrics and Gynecology
OBJECTIVES: To evaluate soluble endoglin (sEng) and the soluble fms-like tyrosine kinase 1 (sFlt1) to placental growth factor (PlGF) ratio for the prediction of preeclampsia in high-risk women, and to evaluate differences in sEng between women with high-risk singleton and multiple gestation pregnancies.
STUDY DESIGN: We collected serial serum specimens from 119 women at high preeclampsia risk. sEng, sFlt1 and PlGF were measured by ELISA.
RESULTS: Among subjects who did not develop preeclampsia, mean serum sEng was significantly higher in those with multiple gestation pregnancies vs. high-risk singletons. Among women with singleton gestations, mean serum sEng was higher in subjects who developed early-onset (<34 >weeks) and late-onset (>or= 34 weeks) preeclampsia, as compared with subjects without preeclampsia, from 22 weeks and 28 weeks gestation onward, respectively. The within-woman rate of change of sEng was also higher in women who later developed preeclampsia.
CONCLUSIONS: sEng is higher in women with multiple gestations vs. high-risk singleton pregnancies. In high-risk women, serum sEng is increased prior to preeclampsia onset.
Rights and Permissions
Citation: Hypertens Pregnancy. 2010;29(3):330-41. Link to article on publisher's site
Maynard, Sharon E.; Moore Simas, Tiffany A.; Bur, Lana; Crawford, Sybil L.; Solitro, Matthew J.; and Meyer, Bruce A., "Soluble endoglin for the prediction of preeclampsia in a high risk cohort" (2010). Obstetrics and Gynecology Publications and Presentations. 8.